title: Arteriovenous access closure in hemodialysis patients with refractory heart failure: a single center experience.
abstract: Arteriovenous dialysis access may impose a burden on the cardiac system. The objective of this study is to examine the usefulness of access closure in hemodialysis patients with refractory heart failure and to identify possible factors associated with symptomatic improvements. The study population comprised 33 hemodialysis patients with symptomatic heart failure (New York Heart Association [NYHA] class ≥ II), who underwent arteriovenous access closure (30 fistulas and three grafts) between 1991 and 2008. In all patients, heart failure was refractory to all possible medical and surgical treatments, and persisted after optimal dry weight control. First, short-term changes in hemodynamics, clinical symptoms and echocardiographic morphology were examined. Second, clinical and echocardiographic parameters were compared between responders (N=23), who demonstrated NYHA class improvement after access closure, and non-responders (N=10). After access closure, systolic blood pressure rose and the heart rate decreased significantly. Body weight and echocardiographic parameters did not change significantly. Twenty-three patients (70%) demonstrated NYHA class improvement and were designated as responders. In responders, the duration from access creation to closure was significantly shorter and fewer had ischemic heart disease, compared with non-responders. Access flow, cardiac output and ejection fraction were comparable between the two groups. Although the five-year survival was 20.2% in all patients, responders showed better early survival than non-responders. Arteriovenous access closure improved clinical symptoms in 70% of patients with refractory heart failure. This improvement was especially likely to be achieved in patients without ischemic heart disease and those who developed heart failure within a relatively short time after access creation.
authors.affiliation: Division of Nephrology, Department of Medicine, Mitsui Memorial Hospital, Tokyo, Japan. kurita_n@opal.plala.or.jp
authors.forename: Noriaki
authors.initials: N
authors.lastname: Kurita
authors.forename: Naobumi
authors.initials: N
authors.lastname: Mise
authors.forename: Shinji
authors.initials: S
authors.lastname: Tanaka
authors.forename: Mototsugu
authors.initials: M
authors.lastname: Tanaka
authors.forename: Keiko
authors.initials: K
authors.lastname: Sai
authors.forename: Takahiro
authors.initials: T
authors.lastname: Nishi
authors.forename: Sumio
authors.initials: S
authors.lastname: Miura
authors.forename: Ikutaro
authors.initials: I
authors.lastname: Kigawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Miyairi
authors.forename: Tokuichiro
authors.initials: T
authors.lastname: Sugimoto
mesh_terms: D000368:Aged; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects*; D001794:Blood Pressure; D006333:Heart Failure / Q000503:physiopathology*; D006339:Heart Rate; D006801:Humans; D007674:Kidney Diseases / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000503:physiopathology; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods*; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome